# References

Brown, R.P., et al., 1997. Physiological parameter values for physiologically based pharmacokinetic models. *Toxicology and Industrial Health*, 13(4), pp.407–484. https://doi.org/10.1177/074823379701300401

Deepika, D. and Kumar, V., 2023. The role of ‘physiologically based pharmacokinetic model (PBPK)’ new approach methodology (NAM) in pharmaceuticals and environmental chemical risk assessment. *International Journal of Environmental Research and Public Health*, 20(4), p.3473. https://doi.org/10.3390/ijerph20043473

DrugBank, 2024. Propranolol. *DrugBank*. Available at: https://go.drugbank.com/drugs/DB00571

Evans, G.H., et al., 1973. The disposition of propranolol. III. Decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. *The Journal of Pharmacology and Experimental Therapeutics*, 186(1), pp.114–122. https://doi.org/10.1016/S0022-3565(25)29572-6

Hung, D.Y., et al., 2004. Disposition kinetics of propranolol isomers in the perfused rat liver. *The Journal of Pharmacology and Experimental Therapeutics*, 311(2), pp.822–829. https://doi.org/10.1124/jpet.104.070011

Jamei, M., et al., 2009. Population-based mechanistic prediction of oral drug absorption. *The AAPS Journal*, 11(2), pp.225–237. https://doi.org/10.1208/s12248-009-9099-y

Jones, H.M. and Yeo, K.R., 2013. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. *CPT: Pharmacometrics & Systems Pharmacology*, 2(8), pp.1–12. https://doi.org/10.1038/psp.2013.41

Jones, H.M., et al., 2006. A novel strategy for physiologically based predictions of human pharmacokinetics. *Clinical Pharmacokinetics*, 45(5), pp.511–542. https://doi.org/10.2165/00003088-200645050-00006

Kaufman, D.P., et al., 2023. Physiology, glomerular filtration rate (GFR). *StatPearls*. National Library of Medicine. Available at: https://www.ncbi.nlm.nih.gov/books/NBK500032

Lee, H.B. and Blaufox, M.D., 1985. Blood volume in the rat. *Journal of Nuclear Medicine*, 26(1), pp.72–76. Available at: https://pubmed.ncbi.nlm.nih.gov/3965655

Lee, M., et al., 2022. Prediction of pharmacokinetics of IDP-73152 in humans using physiologically-based pharmacokinetics. *Pharmaceutics*, 14(6), p.1157. https://doi.org/10.3390/pharmaceutics14061157

Mondal, H. and Saran, L., 2024. Hematocrit (HCT). *StatPearls*. National Library of Medicine. Available at: https://www.ncbi.nlm.nih.gov/books/NBK542276

Nicolaï, J., et al., 2015. Verapamil hepatic clearance in four preclinical rat models: towards activity-based scaling. *Biopharmaceutics & Drug Disposition*, 36(7), pp.462–480. https://doi.org/10.1002/bdd.1959

Potter, D., et al., 1969. Character of function and size in kidney during normal growth of rats. *Pediatric Research*, 3(1), pp.51–59. https://doi.org/10.1203/00006450-196901000-00007

Reigner, B., et al., 1989. Comparative pharmacokinetics of propranolol after administration into the portal and systemic circulation in the rat. *Journal of Pharmacology*, 38(2), pp.112–119. https://doi.org/10.1159/000136352

Rostami-Hodjegan, A., 2012. Physiologically based pharmacokinetics joined with in vitro–in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. *Clinical Pharmacology & Therapeutics*, 92(1), pp.50–61. https://doi.org/10.1038/clpt.2012.65

Rowland, M., et al., 2006. Physiologically based pharmacokinetics in drug development and regulatory science: a workshop report. *Clinical Pharmacokinetics*, 45(5), pp.507–526. https://doi.org/10.2165/00003088-200645050-00006

Rowland, M. and Tozer, T.N., 2011. *Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications*. 4th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins.

Shahrokhi, M. and Gupta, V., 2023. Propranolol. *StatPearls*. National Library of Medicine. Available at: https://www.ncbi.nlm.nih.gov/books/NBK557801/

Shand, D.G., et al., 1972. The disposition of propranolol. *Pharmacology*, 8(4–6), pp.344–352. https://doi.org/10.1159/000136352

Silber, B.M., et al., 1983. Dose-dependent elimination of propranolol and its major metabolites in humans. *Journal of Pharmaceutical Sciences*, 72(7), pp.725–732. https://doi.org/10.1002/jps.2600720703

Simcyp Simulator, 2023. Version 22. Sheffield, UK: Certara UK Limited.

Singh, K., et al., 1991. Determination of in vivo hepatic extraction ratio from in vitro metabolism by rat hepatocytes. *Drug Metabolism and Disposition*, 19(5), pp.990–996. Available at: https://pubmed.ncbi.nlm.nih.gov/1686248

Taegtmeyer, A.B., et al., 2014. A study of the relationship between serum bile acids and propranolol pharmacokinetics and pharmacodynamics in patients with liver cirrhosis and in healthy controls. *PLOS ONE*, 9(6), pp.e97885–e97885. https://doi.org/10.1371/journal.pone.0097885

Taylor, E.A. and Turner, P., 1981. The distribution of propranolol, pindolol and atenolol between human erythrocytes and plasma. *British Journal of Clinical Pharmacology*, 12(4), pp.543–548. https://doi.org/10.1111/j.1365-2125.1981.tb01263.x

Zhao, P., et al., 2012. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. *Clinical Pharmacology & Therapeutics*, 92(1), pp.1–4. https://doi.org/10.1038/clpt.2012.113
